Kleber F X
Med. Klinik u. Poliklinik I, Humboldt-Universität, Berlin, Germany.
J R Soc Med. 1996 Jan;89(1):9-12. doi: 10.1177/014107689608900104.
Quality assurance and inclusion of prospective evaluation of costs of treatment in phase 3 and 4 pharmaceutical trials are becoming increasingly important. Not only high technology applications have to be investigated, but also relatively cheap but very common strategies for diagnostic work up and therapy. This may yield major savings. We are at the beginning of an era in which waste of resources may be reduced by scientific analysis with improvement in patient care and teaching achieved as a result.
质量保证以及将治疗成本的前瞻性评估纳入3期和4期药物试验正变得越来越重要。不仅要研究高科技应用，还要研究诊断检查和治疗中相对便宜但非常常见的策略。这可能会带来大幅节省。我们正处于一个时代的开端，通过科学分析可以减少资源浪费，从而改善患者护理并实现教学目标。
